GlaxoSmithKline's consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the ...

GlaxoSmithKline would consider buying Pfizer’s consumer health business – but only if the price is right, according to the company's chief executive. Emma Walmsley has also been busy shaking ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

If the GSK (LSE: GSK) share price was a video game ... The board has struggled to deliver the promised growth from spinning ...

The new branding also precedes GSK’s proposed demerger this year, which will mean it focuses entirely on biopharma innovation, while its consumer healthcare business, Haleon, will start life as an ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

In this article, we are going to take a look at where GSK plc (NYSE ... play industry groups considered defensive include healthcare, consumer staples, infrastructure, utilities, and others.